financetom
Business
financetom
/
Business
/
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Aug 23, 2024 12:30 AM

Aug 22 (Reuters) - Alzheimer's patients in Britain's

state-run health service is unlikely to get access to Eisai ( ESALF )

and Biogen's new Leqembi drug, after it was

approved by the country's regulator but deemed too expensive for

wide use on Thursday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved